Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  De Monte, Celeste ^a   Carradori, Simone ^a   Granese, Arianna ^a   Di Pierro, Giovanni Battista ^a   Leonardo, Costantino ^a   De Nunzio, Cosimo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Benign prostatic hyperplasia; Content standardization; Extraction techniques; Lipidosterolic composition; Serenoa repens; Supercritical fluid extraction

Indexed keywords

IONIC LIQUID; SABAL EXTRACT; ENZYME; PLANT EXTRACT; SOLVENT;

ARTICLE; ENZYME ASSISTED EXTRACTION; EXTRACTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MEDICINAL PLANT; MICROWAVE ASSISTED EXTRACTION; PRESSURIZED FLUID EXTRACTION; PRESSURIZED LIQUID EXTRACTION; PROSTATE HYPERTROPHY; SABAL; SOLVENT EXTRACTION; SUPERCRITICAL FLUID EXTRACTION; ULTRASOUND ASSISTED EXTRACTION; COMPLICATION; FRACTIONATION; ISOLATION AND PURIFICATION; LOWER URINARY TRACT SYMPTOMS; MALE; MICROWAVE RADIATION; PHARMACOGNOSY; PHYTOTHERAPY; PROCEDURES; PROSTATIC HYPERPLASIA; SUPERCRITICAL FLUID CHROMATOGRAPHY; ULTRASOUND;

CHEMICAL FRACTIONATION; CHROMATOGRAPHY, SUPERCRITICAL FLUID; ENZYMES; HUMANS; IONIC LIQUIDS; LOWER URINARY TRACT SYMPTOMS; MALE; MICROWAVES; PHARMACOGNOSY; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; SOLVENTS; ULTRASONICS;

EID: 84908291885     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-63     Document Type: Article

References (43)

1. The correlation between metabolic syndrome and prostatic diseases. De Nunzio C, Aronson W, Freedland S, Giovannucci E, Parsons JK, Eur Urol 2012 61 560 571
2. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'dow J, Nordling J, de la Rosette JJ, Eur Urol 2013 64 118 140
3. Treatment options for benign prostatic hyperplasia in elderly men. Miano R, De Nunzio C, Asimakopoulos T, Germani S, Tubaro A, Med Sci Monit 2008 14 94 102
4. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Cornu JN, Cussenot O, Haab F, Lukacs B, Eur Urol 2010 58 450 456
5. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. Fourcade RO, Théret N, Taïeb C, BJU Int 2008 101 1111 1118
6. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. Suter A, Saller R, Riedi E, Heinrich M, Phytother Res 2013 27 218 226
7. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. MacDonald R, Tacklind JW, Rutks I, Wilt TJ, BJU Int 2012 109 1756 1761
8. A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Azimi H, Khakshur AA, Aghdasi I, Fallah-Tafti M, Abdollahi M, Inflamm Allergy Drug Targets 2012 11 207 221
9. Serenoa repens for benign prostatic hyperplasia. Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ, Cochrane Database Syst Rev 2012 12 D001423
10. Phytotherapy in the management of benign prostatic hyperplasia. Lowe FC, Urology 2001 58 71 77
11. Development of saw palmetto (Serenoa repens) fruit and extract standard reference materials. Schantz MM, Bedner M, Long SE, Molloy JL, Murphy KE, Porter BJ, Putzbach K, Rimmer CA, Sander LC, Sharpless KE, Thomas JB, Wise SA, Wood LJ, Yen JH, Yarita T, NguyenPho A, Sorenson WR, Betz JM, Anal Bioanal Chem 2008 392 427 438
12. Microwave-assisted extractions of active ingredients from plants. Chan CH, Yusoff R, Ngoh GC, Kung FWL, J Chromatogr A 2011 1218 6213 6225
13. NMR methodologies in the analysis of blueberries. Capitani D, Sobolev AP, Delfini M, Vista S, Antiochia R, Proietti N, Bubici N, Ferrante G, Carradori S, De Salvador FR, Mannina L, Electrophoresis 2014 doi:10.1002/elps.201300629
14. Microwave-assisted extraction of secondary metabolites from plants: current status and future directions. Zhang HF, Yang XH, Wang Y, Trends Food Sci Tech 2011 22 672 688
15. Intensification of extraction of natural products using ultrasonic irradiations-a review of current status. Shirsath SR, Sonawane SH, Gogate PR, Chem Eng Process 2012 53 10 23
16. Isolation of essential oil from different plants and herbs by supercritical fluid extraction. Fornari T, Vicente G, Vàzquez E, Garcìa-Risco MR, Reglero G, J Chromatogr A 2012 1250 34 48
17. Applications of supercritical fluid extraction (SFE) of palm oil and oil from natural sources. Akanda MJ, Sarker MZ, Ferdosh S, Manap MY, Ab Rahman NN, Ab Kadir MO, Molecules 2012 17 1764 1794
18. Application of ionic liquid for extraction and separation of bioactive compounds from plants. Tang B, Bi W, Tian M, Row KH, J Chromatogr B 2012 904 1 21
19. Enzyme-assisted extraction of bioactives from plants. Puri M, Sharma D, Barrow CJ, Trends Biotechnol 2012 30 37 44
20. Pressurized liquid extraction as a green approach in food and herbal plants extraction: A review. Mustafa A, Turner C, Anal Chim Acta 2011 703 8 18
21. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Geavlete P, Multescu R, Geavlete B, Ther Adv Urol 2011 3 193 198
22. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? mechanisms of action. Buck AC, J Urol 2004 172 1792 1799
23. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Habib FK, Wyllie MG, Prostate Cancer Prostatic Dis 2004 7 195 200
24. Comparison of the potency of different brands of Serenoa repens extract on 5-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Scaglione F, Lucini V, Pannacci M, Caronno A, Leone C, Pharmacology 2008 82 270 275
25. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. Raynaud JP, Cousse H, Martin PM, J Steroid Biochem Mol Biol 2002 82 233 239
26. Isolation and pharmacological characterization of fatty acids from saw palmetto extract. Abe M, Ito Y, Suzuki A, Onoue S, Noguchi H, Yamada S, Anal Sci 2009 25 553 557
27. Pharmacologically relevant receptor binding characteristics and 5-reductase inhibitory activity of free fatty acids contained in Saw Palmetto extract. Abe M, Ito Y, Oyunzul L, Oki-Fujino T, Yamada S, Biol Pharm Bull 2009 32 646 650
28. Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility. Chua T, Eise NT, Simpson JS, Ventura S, J Ethnopharmacol 2014 152 283 291
29. Serenoa repens extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells. Baron M, Mancini E, Caldwell A, Cabrelle P, Bernardi F, Pagano F, BJUI 2009 103 1275 1283
30. Lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) treatment affects human prostate cancer cell membrane organization. Petrangeli E, Lenti L, Buchetti B, Chinzari P, Sale P, Salvatori L, Ravenna L, Lococo E, Morgante E, Russo A, Frati L, Di Silverio F, Russo MA, J Cell Physiol 2009 219 69 76
31. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T, BJUI 2012 110 301 E303
32. Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. Silvestri I, Cattarino S, Aglianò AM, Nicolazzo C, Scarpa S, Salciccia S, Frati L, Gentile V, Sciarra A, J Inflammation 2013 10 11 19
33. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, de la Taille A, Terry S, Int J Mol Sci 2013 14 14301 14320
34. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan®) on human carcinoma cell lines. Hostanska K, Suter A, Melzer J, Saller R, Anticancer Res 2007 27 873 882
35. Androgen-independent effects of Serenoa repens extract (Prostasan) on prostatic epithelial cell proliferation and inflammation. Iglesias-Gato D, Carsten T, Vesterlund M, Pousette A, Schoop R, Norstedt G, Phytother Res 2012 26 259 264
36. Characterizing components of the Saw Palmetto Berry Extract (SPBE) on prostate cancer cell growth and traction. Scholtysek C, Krukiewicz AA, Alonso JL, Sharma KP, Sharma PC, Goldmann WH, Biochem Biophys Res Commun 2009 379 795 798
37. Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Yang Y, Ikezoe T, Zheng Z, Taguchi H, Koeffler HP, Zhu WG, Int J Oncol 2007 31 593 600
38. Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H, Arzneimittelforschung 1992 42 547 551
39. Tolerability and toxicity of lipidosterolic extract of American dwarf palm Serenoa repens in Wistar rats: well-known extract, new insight. Duborija-Kovacevic N, Jakovljevic V, Sabo A, Tomic Z, Pajovic B, Perovic D, Eur Rev Med Pharmacol Sci 2011 15 1311 1317
40. Comparative evaluation of the efficiency of prostatotropic agents of natural origin in experimental benign prostatic hyperplasia. Borovskaya TG, Fomina TI, Ermolaeva LA, Vychuzhanina AV, Pakhomova AV, Poluektova ME, Shchemerova YA, Bull Exp Biol Med 2013 155 67 70
41. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Coulson S, Rao A, Beck SL, Steels E, Gramotnev H, Vitetta L, Compl Ther Med 2013 21 172 179
42. Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (flogosis and Profluss in prostatic and genital disease), a multicentre italian study. Morgia G, Cimino S, Favilla V, Russo GI, Squadrito F, Mucciardi G, Masieri L, Minutoli L, Grosso G, Castelli T, Int Braz J Urol 2013 39 214 221
43. Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of Serenoa repens, selenium and lycopene. Minutoli L, Altavilla D, Marini H, Rinaldi M, Irrera N, Pizzino G, Bitto A, Arena S, Cimino S, Squadrito F, Russo GI, Morgia G, J Biomedical Sci 2014 21 19